• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    InMed Announces Changes to its Board of Directors

    8/9/22 7:30:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INM alert in real time by email

    VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately.

    Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets.  Throughout her career, Ms. Lemerond has worked with public and private company management teams and boards to increase stakeholder value.  She established and led healthcare groups at leading investment firms and has also worked at several large financial institutions, including Lehman Brothers and The Carlyle Group.  Ms. Lemerond holds a Bachelor of Science degree from Cornell University and is a CFA charterholder.

    Contemporaneous with Ms. Lemerond's appointment, Adam Cutler has decided to transition off the Board of Directors. Mr. Cutler has served on the Board since 2015, during which time his financial and healthcare expertise has been instrumental in advancing the strategic initiatives of the Company. Over the years, Mr. Cutler has served as Chair of the Audit Committee as well as a member Governance and Nomination Committee. Ms. Lemerond will replace Mr. Cutler as a member of the Audit Committee and as a member of the Governance and Nomination Committee.

    William Garner, MD, InMed's Chairman of the Board of Directors, commented: "I am delighted to welcome Ms. Lemerond to the Board of Directors at InMed. Nicole joins us with tremendous financial and healthcare experience and will prove to be an invaluable asset to the Company. Additionally, on behalf of the Company, I would like to extend our sincere appreciation to Mr. Cutler for his significant contributions over the last 6+ years. His dedication and extensive expertise have been crucial in the strategic development of InMed and we wish him the best with his future endeavors."

    About InMed: InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com and www.baymedica.com.

    Investor Contact:

    Colin Clancy

    Vice President,

    Investor Relations & Corporate Communications

    T: +1.604.416.0999

    E: [email protected]

    Cautionary Note Regarding Forward-Looking Information:

    This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: being a global leader in the research, development, manufacturing and development of rare cannabinoids; and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

    With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Security and Exchange Commission on www.sec.gov.

    All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.



    Primary Logo

    Get the next $INM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INM

    DatePrice TargetRatingAnalyst
    11/29/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $INM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hull Andrew bought $14,625 worth of shares (37,500 units at $0.39), increasing direct ownership by 4,947% to 38,258 units (SEC Form 4)

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      2/22/24 1:38:46 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adams Eric A bought $14,922 worth of shares (41,600 units at $0.36), increasing direct ownership by 1,763% to 43,959 units (SEC Form 4)

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      2/21/24 2:58:17 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hull Andrew

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      2/3/25 8:49:05 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sr VP & General Manager Johnson Shane Aaron

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      12/23/24 9:28:12 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Jagpal Netta

      4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

      12/23/24 9:26:50 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $INM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

      Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-t

      6/27/25 7:00:00 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

      Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred

      6/25/25 8:00:00 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

      Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegenerationReduces key pro-inflammatory markers, independent of amyloid beta or tau pathologyVancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of n

      6/24/25 7:00:00 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on InMed Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $6.00

      11/29/21 6:20:24 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital reiterated coverage on InMed Pharmaceuticals with a new price target

      Roth Capital reiterated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $11.50 from $12.00 previously

      2/16/21 11:09:34 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    SEC Filings

    See more
    • InMed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

      6/30/25 4:16:01 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

      6/24/25 2:35:40 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Registrant's Certifying Accountant, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

      6/13/25 4:30:07 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    Leadership Updates

    Live Leadership Updates

    See more
    • InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

      VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the Company has entered into a service contract (the "Contract") with Brio Financial Group ("Brio") to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022. Brio is a financial and management consulting group based in Bridgewater, New Jersey. The firm provid

      12/12/22 6:47:35 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Announces Changes to its Board of Directors

      VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets.  Throughout her career, Ms. Lemerond has worked with public

      8/9/22 7:30:00 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Announces Appointment of Chief Operating Officer

      VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces Michael Woudenberg has been appointed Chief Operating Officer of the Company, overseeing all day-to-day operations. Mr. Woudenberg was previously Senior Vice President of Chemistry, Manufacturing and Controls. Mike has been an integral part of the executive team for the last four years, supporting multiple functions within the organisation. Prior to joining InMed, Mike had over 20 years of successful drug development, process engineering, GMP manufa

      7/18/22 7:30:00 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    Financials

    Live finance-specific insights

    See more
    • InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022

      VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022. Conference Call & Webcast:Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern TimeRegistration Link: https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a511Webcast Link: https://edge.media-server.com/mmc/p/cnawzqhu(Webcast replay available for 12 months) To access the call by phone, please go to the registration link, and you will be provided w

      9/19/22 6:00:00 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update

      Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseasesCommercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022Advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VANCOUVER, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the development, manufacturing and commercialization of rare cannabinoids,

      2/14/22 7:34:02 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022

      VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will report financial results on Tuesday, February 15, 2022 for the second quarter of fiscal year 2022, ending December 31, 2021. Conference Call & Webcast*:Tuesday, February 15, 2022, at 11:00 AM Pacific Time, 02:00 PM Eastern TimeUS/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745US/CANADA Participant International Dial-In Number: +1 (914) 987-7959Conference ID: 8645175Webcast: https://edge.media-server.com/mmc/p/sa6ykfmv (*Webcast replay available

      2/10/22 7:30:00 AM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc.

      SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

      11/14/24 4:36:01 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by InMed Pharmaceuticals Inc.

      SC 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)

      11/12/24 1:44:16 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc. (Amendment)

      SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

      2/14/24 2:28:27 PM ET
      $INM
      Biotechnology: Pharmaceutical Preparations
      Health Care